The strong pharmaceutical business and international expansion are not yet reflected in the stock price!
I also expect increasing demand in drug supply for 2026. Medios could benefit from this!
The current valuation level seems too low considering the growth rates. Therefore, I expect rising stock prices!
Reading Time: 1 minute
Medios AG (i.) is active as a pharmaceutical wholesaler focusing on chronic and rare diseases such as oncology, multiple sclerosis, hemophilia, and autoimmune disorders, which often require highly specific handling and individual dosing. In November, the company was able to report a revenue increase of 9.2% compared to the previous year's period, particularly thanks to high growth rates in international business as well as in drug supply for the first nine months of the fiscal year, and a disproportionate increase in EBITDA pre of 26.1%. I can well...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
